Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
Phosphoprotein 32 (PP32) is a tumor suppressor that can inhibit several types of cancers, including prostate and breast cancers.
Showing 10 out of 53 products:
results highlight that certain malignancies with ANP32C/D overexpression or mutation might be specifically targeted using Hsp90 (show HSP90 Antibodies) inhibitors.
These findings highlight that certain cancers overexpressing pp32r1 or pp32r1 mutants are likely to demonstrate enhanced resistance to FTY720 treatment.
pp32r1 binds to HuR (show ELAVL1 Antibodies) to avoid the caspase (show CASP3 Antibodies)-mediated decay of HuR (show ELAVL1 Antibodies) in the cytoplasm of cells.
CHD4 (show CHD4 Antibodies) were significantly upregulated by pp32r1 and pp32r1Y140H overexpression which influence a number of cell cycle regulator genes including p53 (show TP53 Antibodies), p21 (show CDKN1A Antibodies) and cyclinD1
Phosphoprotein 32 (PP32) is a tumor suppressor that can inhibit several types of cancers, including prostate and breast cancers. The protein encoded by this gene is one of at least two proteins that are similar in amino acid sequence to PP32 and are part of the same acidic nuclear phosphoprotein gene family. However, unlike PP32, the encoded protein is tumorigenic. The tumor suppressor function of PP32 has been localized to a 25 amino acid region that is divergent between PP32 and the protein encoded by this gene. This gene does not contain introns.
acidic leucine-rich nuclear phosphoprotein 32 family member C
, phosphoprotein 32-related protein 1
, pp32 related 1
, tumorigenic protein pp32r1
, acidic (leucine-rich) nuclear phosphoprotein 32 family, member C